Heparin-induced thrombocytopenia: Myths and misconceptions (That will cause trouble for you and your patient)

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 1961-1964

  Rice, Lawrence ^a,b,c,d  

^a Berlex ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

^c The Medicines Company   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; DEXTRAN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSULTATION; CORRELATION ANALYSIS; DRUG EFFECT; HEALTH SURVEY; HEMATOLOGY; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; MEDICAL PRACTICE; NOTE; OUTCOMES RESEARCH; PHYSICIAN; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VENA CAVA FILTER;

ANTICOAGULANTS; ANTITHROMBINS; HEPARIN; HUMANS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 6344281156     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.18.1961     Document Type: Note

References (25)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101:502-587.
2. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
3. Rice L, Huffman DM, Levine ML, Udden MM, Waddell CC, Luper WE. Heparin-induced thrombocytopenia/thrombosis syndrome: clinical manifestation and insights [abstract]. Blood. 1986;68 (suppl 1):339a.
4. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
5. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:87-121.
6. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
7. Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg. 1988;7:667-672.
8. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
9. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535-555.
10. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
11. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker Inc; 2004:335-370.
12. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210-215.
13. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.
14. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
15. Mims M, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia. Eur J Haematol. 2004;72:366-369.
16. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
17. Warkentin TE, Meddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003;2:148-157.
18. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
19. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103:1838-1843.
20. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950-957.
21. Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol. 2003;71:1-5.
22. Rice L, Attisha WK, Francis JL. Delayed-onset heparin-induced thrombocytopenia [letter]. Ann Intern Med. 2003;139:790-791.
23. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997; 127:804-812.
24. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164: 66-70.
25. Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001; 86:1170-1175.